Posts by Muana Minkoué
Alys Pharmaceuticals launches with $100 Million financing from Medicxi
Formed through the aggregation of six-asset centric Medicxi companies, including Aldena Therapeutics, Alys boasts a robust R&D pipeline of cutting-edge programmes and platforms targeting multiple dermatological indications. Co-founded by Medicxi and several world-leading dermatology and scientific experts, Alys is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. It combines the assets and…
Read MoreCHF 870 Million invested in Swiss medtech and biotech companies
In the midst of an unfavourable environment, the life sciences’ sector continues to attract investors in Switzerland according to the Swiss Venture Capital Report 2024. In 2023, the downturn on the global venture capital market reached Switzerland. Swiss startups received a total of CHF 2.6 Billion last year, 35% less than in 2022.…
Read MoreFONGIT Life Sciences Café+Croissant
The next FONGIT Café+Croissant is taking place on 31 March 2026 at Campus Biotech Geneva in collabortion with CSEM.
Read MoreFirst-in-Human implantation for Novostia’s heart valve
The Vaud-based startup, located at the Biopôle, successfully implanted its TRIFLO valve in a human. Novostia, a pioneering medical technology company, proudly announces a significant milestone in its mission to revolutionize cardiovascular care. Last December, the company has successfully implanted its groundbreaking TRIFLO Heart Valve in a human patient for the first time.…
Read MoreDebiopharm Innovation Fund invests in MedaSystems
MedaSystems secures additional funding from Debiopharm Innovation Fund to accelerate global access to pre-approval treatment. Medasystems, a pioneer in software to provide access to pre-approval medicine, announced funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling…
Read MoreCellestia secures a CHF 2 Million grant from Innosuisse
The Biopôle based startup was awarded an Innosuisse Grant to advance a groundbreaking Graft versus Host Disease prevention therapy. Cellestia Biotech AG (Cellestia) announced its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Startup Innovation project to advance to clinical Proof of Concept, a…
Read MoreDIA Europe
DIA Europe 2026 is taking place from 16 to 18 March 2027 in Basel DIA Europe 2027 brings together life sciences professionals from across the globe for three days of cutting-edge science, regulatory dialogue, and cross-sector collaboration in the heart of one of Europe’s most dynamic cities. Join 1,500+ life sciences professionals from…
Read More